The trouble with small problems is that they can easily become big ones. Who would have thought that a single shot fired in Sarajevo in 1914 would have led to two world wars and a cold war lasting 50 years? While not on the same scale, but certainly the same principle, who knows where the industry's action against the South African government over the patents on AIDS products will lead?
In my opinion, the industry is heading on a dangerous path in its case against South Africa and its leaders must think very carefully before going any further. The best generals are those who know when to fight and when to withdraw. They will tell you that there is no point in fighting a battle unless there is something substantial to be gained. So what is to be gained in the courtroom in South Africa?
The issue of supplying essential pharmaceuticals to the less developed countries of the world has been going on for years. Access to AIDS drugs for South Africa is nothing new. I first came up against the problem in the early 1970s when Ciba Geigy developed a product for the intestinal parasitic disease, Bilharzia (schistosomiasis). Then, the Egyptian government demanded that it should be supplied at knock down prices on humanitarian grounds given the enormity of the problem for the country at the time.
As I recall, Ciba Geigy stood firm in the face of the Egyptian demands, pointing out that even if those who benefit from the therapy were successfully treated, they would become ill again whenever they went in infected water. The problem was an environmental one and not one of treating sick patients. I believe the issue was solved when Shell came up with a compound which killed the waterborne infectious agent at a very low cost, so matters went no further. Now, we have a similar situation in South Africa, but here the problem is not an environmental one, rather one of public health, education and general social behavior. In saying this, I am very aware that we who live in affluent countries must not take a patronizing, "know it all" attitude when discussing the problems of countries which are less well off than ours, which means that we must deal, as far as possible, with hard facts and common sense.
In my analysis of the situation, first I would point out that involvement in treating Third World illnesses is not the core business of the international pharmaceutical industry. The industry operates in the main in developed countries where its industrial property rights, ie patents and trademarks, are accepted and upheld. If pharmaceutical companies did not have this industrial protection, they could not have developed in the way they have for the past 60 years. The patent monopoly granted to a company not only secures its business but also gives it rights to charge the prices needed to sustain its activities. If it is forced to charge generic prices then what is the point of having a patent?
The international R&D-based pharmaceutical industry sells products that treat the diseases of the Western world. At the start of the 21st century, these are diseases of the cardiovascular system, neurological diseases, cancer and illnesses associated with Western lifestyle, obesity and the like. In these cases, affluent countries are prepared to pay up to US$10,000 a year to treat a patient, which is way beyond the means, and well outside the political will, of poorer countries.
Clearly, when we have a disease which spans both rich and poor countries, such as AIDS, we have a problem. One could ask the question why the pharmaceutical industry should be interested in providing treatment for AIDS since it has a very low incidence in the sophisticated societies where other measures can be taken to combat the condition, such as education and the use of condoms. The fact is that the R&D-based companies have developed AIDS drugs for the wealthy patients of Europe, North America and elsewhere, and not for the poor patients in Africa, just as they have developed drugs for the treatment of cancer, heart disease, Alzheimer's and the like. Around 1.5 billion people benefit from the drugs developed by the international R&D-based pharmaceutical industry, 4.5 billion people do not.
This brings me to the second point, which is that the pharmaceutical industry is not a substitute for a country's national health service. The reason why countries in Europe can afford the prices charged by R&D-based companies is because they commit significant financial resources to the provision of healthcare for their populations. Importantly, they also commit significant financial resources to education, social security, public health, the environment, communication and transportation. The governments in these countries ensure that everything is done to support a healthy and productive society that can thrive and prosper. The pharmaceutical industry is just one component in this mix, a valuable component to be sure, but still just one component.
The problem in the poorer countries is that they do not allocate their service resources in order to maximize the productivity and prosperity of their citizens. They spend disproportionate amounts of money on their armies and weapons systems, national security being their main preoccupation, and in some [countries] huge amounts of state money are siphoned off by corrupt rulers into foreign bank accounts. In many of the poorer countries where TB and malaria are rampant, generic, out of patent drugs are in fact available at costs amounting to a few pence a day, but still they are not deployed to the benefit of the community. As in the Egyptian case, even if individuals were cured of TB and malaria, the problem would not be solved while the environmental hazards remain.
So for the poorer countries, the pharmaceutical industry does not provide the benefits that it does in the wealthier ones. In fact, to bring this point home, I asked a number of pharmaceutical company executives whether they thought that making AIDS drugs available to the poor of South Africa would have any effect on the incidence of the disease in that country, and not one said they would. The treatment of AIDS is not simply a matter of giving a patient a once-a-week pill. It involves multiple dosing with an increasing number of drugs as the condition worsens, and the drugs themselves have serious side effects that have to be tolerated. When such treatments are considered in the context of conditions prevailing in many African countries, one seriously questions whether a beneficial outcome is possible.
It is when one gets down to the specifics of the South African case that things become more complicated, and this leads me to my third point, which is whether the R&D-based pharma industry should become involved in a legal fight with that country's government over patent rights of AIDS drugs.
It is important to remember that South Africa is a special case among the poorer nations of the world because of the legacy of apartheid. It is special because its black and colored population suffered such abomination at the hand of the whites, and now the black population rules the country, as many think is right and proper. And, of course the transfer of power and authority took place under Nelson Mandela, a man of remarkable qualities whatever one's political point-of-view. If ever an industry wanted to take on a country, the last one it should choose should be South Africa.
Yes, silly things have been said about the nature and origin [of HIV] by Nelson Mandela's successor, Thabo Mbeki. Yes, South Africans are plagued by AIDS and their plight has been brought to the attention of the world by the likes of Oxfam and Médecins Sans Frontières. Yes, the Indian company Cipla has said that it can provide the AIDS drugs at a substantial discount on the price being charged in Europe, and another Indian company has said that it can provide them even cheaper and we have not got to the Chinese yet! Yes, the international companies have claimed that they have patent rights that apply in South Africa. So we have all the makings of a good old-fashioned punch up. Right is on both sides and only a judge can sort it out. Is that what the international industry really wants?
Well now some are not so sure. Thinking has shifted and a number of companies are offering to supply their AIDS drugs at significant discounts. As time passes, these discounts have become more and more significant to the point where they reach levels where there is virtually no difference between the Cipla price and that being offered by the R&D-based companies. But is this the right answer? On the one hand, we have companies which want to have their day in court arguing the rights of their patents. On the other, we have those who are discounting so hard that they have made their products into generics.
Before the South African court comes to order and the lawyers start to argue their cases, just pause for a moment and consider what the outcome will be. On the one hand, the industry could win its case to the embarrassment of the government which would appeal and, I suspect, win on appeal. Or the industry could lose, and have to endure the howls of triumph that would follow not only in South Africa, but in countries throughout the world, both rich and poor. But there would not only be howls of triumph. In the wake of a South African triumph, every health minister in every country, aided and abetted by the local AIDS patients' lobby, would be beating at the doors of the industry demanding that AIDS drugs should be made available at cut prices. And after AIDS, what next?
My advice to the industry is cut and run. Do not fight the South African case. Leave the market to Cipla and other generic firms whose prices and supply lines may not hold, who knows? I also suggest that one logical conclusion which could be drawn from the South African experience is that companies re-examine their involvement in AIDS R&D and concentrate on research for diseases that relate solely to the Western world which the Western world values. Remember the pharmaceutical companies are businesses, not charities. ■ 
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